AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 AUG 5 - (NewsRx.com & NewsRx.net) -- A novel radiolabeled peptide may facilitate diagnosis of breast cancer.
"In an effort to develop a peptide-based radiopharmaceutical for the detection of breast cancer," scientists in Saudi Arabia "prepared an analog of alphaM2 peptide, modified to incorporate an N3S chelate system."
"Mercaptoacetyltriglycine (MAG)[subscript]3-derivatized alphaM2 peptide was prepared by solid-phase synthesis and radiolabeled with [superscript]99mTc by an exchange method," explained S.M. Okarvi and coauthors at the King Faisal Specialist Hospital & Research Center in Riyadh.
"In vitro cell-binding on human breast cancer cell lines, MDA-MB-231 and MCF-7, indicated the affinity and specificity of [superscript]99mTc-MAG[subscript]3-alphaM2 toward breast cancer cells," the collaborators said. "Additionally, the radiolabeled peptide showed rapid internalization into human breast cancer cells."
"In vivo biodistribution in mice showed that the radiolabeled peptide cleared rapidly from the blood and most non-target tissues and was excreted significantly via the kidneys," published data showed. "Uptake of [superscript]99mTc-MAG(3)-alphaM2 in the tumor was ...
Source: HighBeam Research, Radiolabeled peptide shows promise for diagnosis.